Home » Dr Reddy’s Acquires 80 Percent Shares in OctoPlus

Dr Reddy’s Acquires 80 Percent Shares in OctoPlus

January 7, 2013

Dr Reddy’s Laboratories, which is in the process of acquiring Netherlands-based specialty pharmaceutical company OctoPlus NV for about US $36 million, has so far managed to get nearly 80 per cent shares in its favour.
The Economic Times

05Aug
Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management
10Aug
Is Biosimilars Regulation Taking a Major Turn?: The Latest Must-Know Developments, Including BsUFA III
12Aug
On-Site Inspections: They’re Back — But When, Where and How
16Aug
Using AI for CAPA and Root Cause Investigation
28Sep
4th Annual WCG MCC Clinical Trial Risk & Performance Management Collaborative vSummit
12Oct
Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

Dr Reddy’s Acquires 80 Percent Shares in OctoPlus

Upcoming Events

Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

Is Biosimilars Regulation Taking a Major Turn?: The Latest Must-Know Developments, Including BsUFA III

On-Site Inspections: They’re Back — But When, Where and How

Using AI for CAPA and Root Cause Investigation

4th Annual WCG MCC Clinical Trial Risk & Performance Management Collaborative vSummit

Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

First Interchangeable Biosimilar Insulin Secures FDA Approval

Lazarus Gets FDA 510(k) Clearance for Pre-Sure Surgical Technology

Celltrion Gets Priority Review in Canada for COVID-19 Antibody

Lantheus Gets FDA Clearance for Prostate Cancer Software

The Revised ICH E8: A Guide to New Clinical Trial Requirements